1Kahn P. Juvenile idiopathic arthritis: current and future therapies [J]. Bull NYU Hosp J Dis,2009,67(3) :291-302.
2Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001 [J]. J Rheumatol, 2004,31 (2) : 390-392.
4Masters SL, Simon A, Aksentijevich 1, et al. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease [J ]. Annu Rev lmmunol, 2009,27:621-628.
5Reiff A. The use of anakinra in juvenile arthritis [J]. Curr Rheumatol Rep, 2005,7 (6) : 434-440.
6Mirkinson LJ, Katona IM. Systemic onset juvenile idiopathic arthritis: update on pathogenesis and treatment [J]. Expert RevClin Immunol, 2007,3 (3) : 313-321.
7Gatlorno M, Pieeini A, Lasiglie D, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemiconset juvenile idiopathic arthritis [J]. Arthritis Rheum,2008,58(5 ) : 1505-1515.
8Ravelli A, Martini A. Juvenile idiopathic arthritis [J]. Lancet, 2007,369 (9563) : 767-778.
9Kotto-Kome AC, Fox SE, Lu W, et al. Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharalacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model [J]. Pharrnaeol Res,2004,50(1):55-58.
10Hawkins PN, Laehmann HJ, Aganna E, et al. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra [J ]. Arthritis Rheum,2004,50(2) :607-612.
9Model1 V, Gee B, Lewis DB, et al. Global study of primary immunodeficiency diseases (PI)-diagnosis, treatment, and economic impact: an updated report from the Jeffrey Model Foundation [ J ]. Immunol Res, 2011,51 : 61-70.
10Wang LL, Jin YY, Hao YQ, et al. Distribution and clinical features of primary immunodeficiency diseases in Chinese children (2004-2009) [J]. J Clin Immunol, 2011, 31 (3) : 297-308.
